China’s HG Capital Leads $23M Round In Nuokangda Pharmaceutical

Chinese private equity firm HG Capital has invested RMB160 million (US$23 million) in Beijing Nuokangda Pharmaceutical Technology Co., Ltd, a contract research organization focused on innovative medicine, supplements and medical equipment, according to a Chinese media report.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

China Expert network

LEAVE A REPLY